21 completed, 4 recruiting, 3 active not recruiting, 3 terminated. 16 Phase 1, 14 Phase 2, 5 Not applicable, 1 Phase 3.
Follow Acute Undifferentiated Leukemia: new trials by email Literature Review of Acute Undifferentiated Leukemia trials Research Report on Acute Undifferentiated Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-09-01 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Clofarabine, Cytarabine, Dexamethasone - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2014-10-27 | 2024-03-22 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2014-04-10 | 2024-03-12 |
| Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia bioelectric impedance analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Not applicable | Completed | Wake Forest University Health Sciences | 102 | 2013-07-01 | 2020-08-13 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 46 | 2010-05-19 | 2023-01-23 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
Showing 20 of 34. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (30) · Leukemia, Myeloid, Acute (22) · Burkitt Lymphoma (14) · Leukemia, Mast-Cell (14) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Blast Crisis (12) · Hodgkin Disease (12) · Leukemia, Myelomonocytic, Chronic (12) · Lymphoma, Large-Cell, Anaplastic (12) · Lymphoma, T-Cell, Cutaneous (12) · Intraocular Lymphoma (11) · Leukemia, Hairy Cell (11) · Lymphoma, Large B-Cell, Diffuse (11) · Mycosis Fungoides (11)
Hemic and Lymphatic Diseases (34) · Immune System Diseases (34) · Immunoproliferative Disorders (34) · Leukemia, Lymphoid (34) · Lymphatic Diseases (34) · Lymphoproliferative Disorders (34) · Neoplasms (34) · Neoplasms by Histologic Type (34) · Hematologic Diseases (32) · Leukemia (28) · Bone Marrow Diseases (27) · Leukemia, Myeloid (27) · Chronic Disease (23) · Disease Attributes (23) · Pathologic Processes (23)
Whole-Body Irradiation (11) · fludarabine phosphate (10) · Cyclophosphamide (8) · Mycophenolic Acid (8) · Peripheral Blood Stem Cell Transplantation (7) · Filgrastim (6) · Methotrexate (6) · Cytarabine (5) · Vincristine (5) · fludarabine (5) · Cyclosporine (4) · Dexamethasone (4) · Granulocyte Colony-Stimulating Factor (4) · Tacrolimus (4) · Biopsy (3)
Fred Hutchinson Cancer Center (11) · National Cancer Institute (NCI) (9) · Ossium Health, Inc. (3) · Wake Forest University Health Sciences (3) · Children's Oncology Group (2) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Syndax Pharmaceuticals (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · University of Florida (1)
United States (32) · Canada (5) · Australia (3) · Italy (3) · New Zealand (2) · Germany (1) · Puerto Rico (1) · Switzerland (1)
Marie Bleakley (3) · David Maloney (2) · Adam Lamble, MD (1) · Ann Woolfrey (1) · Brenda Cooper (1) · Brenda Sandmaier (1) · Brenda Weigel (1) · Denise Correa, PhD (1) · Elias Jabbour (1) · Elizabeth Krakow (1) · Janet Tooze, PhD (1) · Joanne M Hilden (1) · John Deeken (1) · Jordan Milner, MD (1) · Mark Kirschbaum (1)
PMID 32499241, PMID 35007144, PMID 18698002, PMID 22259028, PMID 23393050, PMID 24474568, PMID 32414848, PMID 33049057, PMID 36402456, PMID 38683966
P01CA018029 (5), P30CA015704 (5), U01CA062505 (3), U01CA097452 (3), R01HL121568 (2), U01CA062502 (2), U10CA098543 (2), K23CA154532 (1), N01CM62202 (1), P01CA078902 (1), P30CA012197 (1), U01CA062487 (1), U01CA062491 (1), U01CA099168 (1), U01CA121947 (1)